Key result
Following an acute coronary event, 15.1% of patients on ASA monotherapy and 37.5% on dual antiplatelet therapy discontinued treatment within 1 year, with bleeding as the strongest predictor.
Why the study?
What are the trends in prescription and discontinuation of antiplatelet therapy following an acute coronary event in UK primary care?
Observational (n=27,351)
What are the trends in prescription and discontinuation of antiplatelet therapy following an acute coronary event in UK primary care?
Despite high initial prescription rates of antiplatelet therapy post-acute coronary event, a substantial proportion of patients discontinue treatment within 1 year, often driven by bleeding events.
Answers are grounded in this paper and cite their sources.
High discontinuation rates post-event, especially DAPT driven by bleeding, warrant monitoring; observational data leaves open strategies to improve persistence.
BACKGROUND: Antiplatelet (AP) therapy is well established for the secondary prevention of acute coronary events. However, patients may discontinue treatment, often owing to gastrointestinal (GI) complications, leaving them at elevated risk of recurrent cardiovascular events. OBJECTIVES: This descriptive retrospective study assessed trends in prescription of AP agents and coprescription of gastroprotective therapy, after an acute coronary event. Discontinuation of AP therapy within 2 years of an event and factors predicting discontinuation were investigated. METHODS: The study was conducted in a UK primary care setting from 2000 to 2008; a total of 27, 351 patients aged 50 to 84 years were included in the analysis. Main outcome measures were exposures to low-dose acetylsalicylic acid (ASA), clopidogrel, and proton pump inhibitors (PPIs). RESULTS: At 90 days after an acute coronary event, 85.9% of patients had been prescribed some form of AP therapy and 33.6% of patients who were issued at least 1 ASA prescription in this period were also issued a PPI prescription. The use of dual antiplatelet therapy (DAT) 90 days after an event increased from 2% in 2000 to over 50% in 2008. An estimated 15.1% of patients on ASA monotherapy and 37.5% on DAT discontinued treatment within 1 year. A bleeding event during follow-up, including upper GI bleeding or hemorrhagic stroke, was the strongest predictor of discontinuation. CONCLUSION: Although most patients were prescribed AP therapy in the 90 days following an acute coronary event, a substantial proportion discontinued DAT or ASA monotherapy within 1 year. It is essential that physicians consider strategies to reduce the risk of discontinuation of AP therapy.
No takes yet. Share an insight, caveat, or question.
Sáez et al. (2014) conducted an observational in Acute coronary event (n=27,351). Antiplatelet therapy was evaluated on Exposure to and discontinuation of antiplatelet therapy. Following an acute coronary event, 15.1% of patients on ASA monotherapy and 37.5% on dual antiplatelet therapy discontinued treatment within 1 year, with bleeding as the strongest predictor.
Synapse has enriched 10 related papers. Consider them for comparative context: